Navigation Links
Helix BioPharma Reports On 2009 Annual General Meeting
Date:12/9/2009

AURORA, Ontario, Dec. 9 /PRNewswire-FirstCall/ -- Helix BioPharma Corp. (TSX, FSE: HBP; OTCQX: HXBPF) reports that at its Annual General Meeting held today, shareholders approved all of management's proposals.

Board of Directors

All seven Board members were re-elected as directors, with the Board continuing to be constituted of:


Donald H. Segal, Chairman of the Board and Chief Executive Officer
Kenneth A. Cawkell, Director and Corporate Secretary
John Docherty Director, President and Chief Operating Officer
Thomas Hodgson, Director
Jack Kay, Director
Gordon M. Lickrish, Director
Kazimierz Roszkowski-Sliz, Director

Auditor

KPMG LLP was re-appointed as the Company's auditor.

By-Law No. 1 (2009)

The shareholders approved the repeal of former By-Law No. 1 and the adoption of new By-law No. 1 (2009) of the Company. By-law No. 1 (2009) as approved is being filed on SEDAR at www.sedar.com and on EDGAR at www.sec.gov/edgar.shtml.

Corporate Presentation

The slide show portion of the corporate presentation given at the meeting has been posted on the Company's website at www.helixbiopharma.com.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is listed on the TSX and FSE under the symbol "HBP" and on the OTCQX International Market under the symbol "HXBPF".


For further in
'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Helix BioPharma Corp. Announces Fiscal Q1 2010 Results
2. Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
3. Helix BioPharma Corp. Announces Fiscal 2009 Results
4. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
5. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
6. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
7. Seven New Biopharmaceutical Research Companies Join PhRMAs Mission to Advance Medical Innovation
8. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
9. PDL BioPharma Announces December 15 Special Dividend Payment of $1.67 per Share
10. Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
11. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... and MENLO PARK, Calif. , ... Inc. (OTCQB: DMPI) ("DelMar" "the Company") today announced ... statements.  The Company recently changed its fiscal year end ... to list its common stock on a national securities ... financial statements as filed with the United States Securities ...
(Date:8/29/2014)... AMSTERDAM , August 29, 2014 ... invited to participate in the inaugural Tweetchat taking ... CPhI Worldwide , organised by UBM ... October 2014. #CPhIChat is a first of its ... media working across the supply chain, aimed to ...
(Date:8/28/2014)... 2014  Rigrodsky & Long, P.A.: , Do ... LCI )? , Did you purchase your shares ... 16, 2014, inclusive? , Did you lose money in ... want to discuss your rights? Rigrodsky ... Timothy J. MacFall , announces that a complaint has been ...
Breaking Medicine Technology:DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 2CPhI Worldwide to Host #CPhIChat Provoking Debate on the Future of Pharma 3Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 3
... March 31, 2011 Reportlinker.com announces that ... in its catalogue: Gout ... Therapies such as Krystexxa, Uloric, Adenuric and ... http://www.reportlinker.com/p0464105/Gout-Therapeutics-Market-to-2017--Entry-of-Novel-Therapies-such-as-Krystexxa-Uloric-Adenuric-and-Colcrys-to-Drive-Market.html Gout Therapeutics ...
... that a new market research report is available in ... Testing Markets http://www.reportlinker.com/p089570/Cardiac-Marker-Diagnostic-Testing-Markets.html ... is to describe the specific market segment of the ... testing. This study examines clinical measurement devices and their ...
Cached Medicine Technology:Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 2Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 3Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 4Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 5Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 6Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 7Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 8Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 9Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 10Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 11Reportlinker Adds Gout Therapeutics Market to 2017- Entry of Novel Therapies such as Krystexxa, Uloric, Adenuric and Colcrys to Drive Market 12Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 2Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 3Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 4Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 5Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 6Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 7Reportlinker Adds Cardiac Marker Diagnostic Testing Markets 8
(Date:8/30/2014)... is a common problem millions of American cope with every day. ... nuisance, for some, it can have a crippling impact on social ... dramatic mood swings and depression. , Those struggling with acne ... In some cases, that can make the problem even worse. Instead ... a quest for clearer skin can now view acne treatment ...
(Date:8/30/2014)... Manhattan Beach, Calif. (PRWEB) August 30, 2014 ... Carol Francis helps listeners understand how they unknowingly developed insomnia ... and have restful nights during. Tune in to the ... . The show airs live on August 30, and ... For more information on programming, go to DrCarolFrancisTalkRadio.com. ...
(Date:8/30/2014)... Hastings and Hastings, a qualified team of knowledgeable ... pleased to report having saved a client $67,100 on ... cases where Hastings and Hastings has tailored its fees ... portion of their settlement or recovery. The firm has ... for Arizona car accident victims is achievable through dedicated ...
(Date:8/30/2014)... "My niece developed a nighttime fever, and ... her fever might get worse," said an inventor from ... of how she was doing, I developed this monitoring ... monitor a child's temperature. The unit instantly alerts parents ... prompt medical care can be given, which is designed ...
(Date:8/30/2014)... 30, 2014 "I had a handicapped friend ... crutches," said an inventor from Wetumpka, Ala. "In order to ... of the shore, I came up with a way for ... created a prototype for the patent-pending Deezers to allow crutches ... individual to use crutches, walkers, or canes at the beach. ...
Breaking Medicine News(10 mins):Health News:Acne Treatment Reviews Added to Popular Treatment Website 2Health News:Sleepless Nights, Exhausting Days, Mental Fog – Relief for Insomnia With Clinical Psychologist Dr. Carol Francis 2Health News:Hastings and Hastings Is Pleased To Report Having Saved A Client $67,100 On A Settlement Of $610,000 2
... Recommend Photochromic Lenses to Protect Eyes This Summer and ... Throughout the ... the dangers of extended sun exposure and its effects on the skin, ... survey conducted by,the New England Eye Institute and Transitions Optical found that ...
... to vote soon on legislation that would cut ... WASHINGTON, July 9 Seniors across Texas ... Advantage program in,legislation being considered in the U.S. ... from the Medicare Advantage program in Texas,alone and ...
... Additional Research Warranted on Impact of Medicare Modernization ... Shows Possibility of,Longer Wait Times for Patients in ... to a new study,released today in the July ... (JAMA), cancer patients experienced no major changes in ...
... 2006, a pneumococcal vaccine (Prevenar) was introduced in the ... experiences have been published in the journal Vaccine ... pneumococcal infections among young children. , Pneumococcus is ... young children, e.g. meningitis, blood poisoning and pneumonia. Most ...
... lumpectomy linked to depression, fear, study finds , , WEDNESDAY, ... who opt for breast-conserving cancer surgery say they now ... their quality of life, a new study says. , ... were twice as likely to fear their cancer returning ...
... Razadyne ER,from Tier 2 to Tier 3 When Generic Razadyne ... ... WALTHAM, Mass., July 9 Decision Resources, one of ... finds that the generic availability of,Shire/Janssen/Ortho McNeil,s Razadyne (galantamine) in ...
Cached Medicine News:Health News:Study Confirms Americans Place Their Vision at Risk Year Round 2Health News:Study Confirms Americans Place Their Vision at Risk Year Round 3Health News:Texas Seniors Speak Out Against Medicare Advantage Cuts 2Health News:Global Access Project (GAP) Study Examining Patients' Access to Cancer Care Featured in the Journal of the American Medical Association (JAMA) 2Health News:Vaccinated infants well-protected against severe pneumococcal infection in Norway 2Health News:Breast-Conserving Surgery Leaves Many Cancer Patients Disappointed 2Health News:Primary Care Physicians' Prescriptions of Aricept for Alzheimer's Disease Will Drop by 20 Percent Following the Availability of Generic Razadyne in December 2008 2Health News:Primary Care Physicians' Prescriptions of Aricept for Alzheimer's Disease Will Drop by 20 Percent Following the Availability of Generic Razadyne in December 2008 3
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Escherichia coli - For the qualitative detection of Escherichia coli 0157 and 0157:H7 in food products. Accessories BinaxNOW EH E.coli 0157 & 0157:H7 Control Swab Pack (510-000), BinaxNow E.coli...
For the qualitative detection of antibodies to Treponema pallidum in human serum, plasma and whole blood specimens...
Medicine Products: